The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis
Open accessAbstract
BACKGROUND Cardiotoxicity is a well-recognised complication of chemotherapy with anthracycline and/or trastuzumab, and its prevention remains an important challenge in cancer survivorship. Several successful preventative strategies have been identified in animal trials. We sought to assemble the clinical evidence that prophylactic pharmacological interventions could prevent left ventricular (LV) dysfunction and heart failure in patients undergoing chemotherapy. METHODS We undertook a systemic review of the evidence from randomised trials and observational studies where a prophylactic intervention was compared with a control arm in patients with a normal ejection fraction and no past history of heart failure. The primary outcome was development of heart failure (HF), a drop in ejection fraction (EF) or both. A random-effects model was used to combine relative risks (RR) and 95% confidence intervals (CIs), and a meta-regression was undertaken to assess the impact of potential covariates. FINDINGS Data were collated from 14 published articles (n=2015 paediatric and adult patients) comprising 12 randomised controlled trials and two observational studies. The most studied chemotherapeutic agents were anthracyclines, and prophylactic agents included dexrazoxane, statins, beta-blocker and angiotensin antagonists. There were 304 cardiac events in the control arm compared to 83 in the prophylaxis arm (RR=0.31 [95% CI: 0.25-0.39], p<0.00001). Cardiac events were reduced with dexrazoxane (RR=0.35 [95% CI 0.27-0.45], p<0.00001), beta-blockade (RR=0.31 [95% CI 0.16-0.63], p=0.001), statin (RR=0.31 [95% CI 0.13-0.77], p=0.01) and angiotensin antagonists (RR=0.11 [95% CI 0.04-0.29], p<0.0001). INTERPRETATION Prophylactic treatment with dexrazoxane, beta-blocker, statin or angiotensin antagonists appear to have similar efficacy for reducing cardiotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Spagnuolo, R. D., Recalcati, S., Tacchini, L., & Cairo, G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01208.x · Cited by 42
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Chronic Health Conditions in Adult Survivors of Childhood Cancer
Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa060185 · Cited by 3,597
Anderson, E. N. (1977) · eScholarship (California Digital Library) · Cited by 2,567
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Anthracycline-Induced Cardiomyopathy
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.095 · Cited by 1,105
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,026
EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary
Sant, M., Allemani, C., Santaquilani, M., Knijn, A., Marchesi, F., & Capocaccia, R. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.018 · Cited by 1,021
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention
Pai, V. B., & Nahata, M. C. (2000) · Drug Safety · doi:10.2165/00002018-200022040-00002 · Cited by 729
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Bosch, X., Rovira, M., Sitges, M., Domènech, A., Ortiz-Pérez, J. T., de Caralt, T. M., Morales-Ruiz, M., Perea, R. J., Monzó, M., & Esteve, J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.072 · Cited by 632
Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Doroshow, J. H. (1983) · PubMed · Cited by 629
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 551
Subcellular effects of adriamycin in the heart: A concise review
SINGAL, P., DEALLY, C., & WEINBERG, L. (1987) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(87)80392-9 · Cited by 465
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
Ewer, M. S., & Ewer, S. M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.121 · Cited by 373
Seicean, S., Seicean, A., Plana, J. C., Budd, G. T., & Marwick, T. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.067 · Cited by 326
Self-citationICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A., Wernz, J. C., Rey, M., Sanger, J., Kramer, E., Ferrans, V, Hochster, H., & Meyers, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.117 · Cited by 322
Kalyanaraman, B., Perez-Reyes, E., & Mason, R. P. (1980) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(80)90142-7 · Cited by 317
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313
Silber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J., Hogarty, A. N., Cohen, M. I., Barber, G., Rutkowski, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.022 · Cited by 299
Shankar, S. M., Marina, N., Hudson, M. M., Hodgson, D. C., Adams, M. J., Landier, W., Bhatia, S., Meeske, K., Chen, M. H., Kinahan, K. E., et al. (2008) · Pediatrics · doi:10.1542/peds.2007-0575 · Cited by 283
Clinical Cardiac Tolerability of Trastuzumab
Perez, E. A., & Rodeheffer, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.120 · Cited by 280
Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy
Acar, Z., Kale, A., Turgut, M., Demircan, S., Durna, K., Demir, S., Meriç, M., & Ağaç, M. T. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.025 · Cited by 255
Ho, E., Brown, A., Barrett, P., Morgan, R. B., King, G., Kennedy, M. J., & Murphy, R. T. (2010) · Heart · doi:10.1136/hrt.2009.173997 · Cited by 242
Dunn, F. G., Oigman, W., Ventura, H. O., Messerli, F. H., Kobrin, I., & Frohlich, E. D. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90692-1 · Cited by 236
Oliveira, P. J., Bjork, J. A., Santos, M. S., Leino, R. L., Froberg, M. K., Moreno, A. J., & Wallace, K. B. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.005 · Cited by 227
Wexler, L. H., Andrich, M. P., Venzon, D., Berg, S. L., Weaver-McClure, L., Chen, C. C., Dilsizian, V, Avila, N., Jarosinski, P., Balis, F. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.362 · Cited by 224
Pretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice
Riad, A., Bien, S., Westermann, D., Becher, P. M., Loya, K., Landmesser, U., Kroemer, H. K., Schultheiss, H. P., & Tschöpe, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3076 · Cited by 205
Huang, C., Zhang, X., Ramil, J. M., Rikka, S., Kim, L., Lee, Y., Gude, N. A., Thistlethwaite, P. A., Sussman, M. A., Gottlieb, R. A., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.902221 · Cited by 203
Marty, M., Espié, M., Llombart, A., Monnier, A., Rapoport, B. L., & Stahalova, V. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj134 · Cited by 202
Walker, J., Bhullar, N., Fallah-Rad, N., Lytwyn, M., Golian, M., Fang, T., Summers, A. R., Singal, P. K., Barac, I., Kirkpatrick, I. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7294 · Cited by 198
Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Curigliano, G., Mayer, E. L., Burstein, H. J., Winer, E. P., & Goldhirsch, A. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.05.006 · Cited by 166
Venturini, M., Michelotti, A., Del Mastro, L., Gallo, L., Carnino, F., Garrone, O., Tibaldi, C., Molea, N., Bellina, R. C., Pronzato, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.12.3112 · Cited by 165
Seicean, S., Seicean, A., Alan, N., Plana, J. C., Budd, G. T., & Marwick, T. H. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.000055 · Cited by 165
Self-citationLópez, M., Vici, P., Lauro, K. D., Conti, F., Paoletti, G., Ferraironi, A., Sciuto, R., Giannarelli, D., & MAINI, C. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.86 · Cited by 140
Ibrahim, M. A., Ashour, O. M., Ibrahim, Y. F., EL-Bitar, H. I., Gomaa, W. M., & Abdel-Rahim, S. R. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.05.007 · Cited by 126
Carvedilol: Molecular and Cellular Basis for Its Multifaceted Therapeutic Potential
Cheng, J., Kamiya, K., & Kodama, I. (2001) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2001.tb00061.x · Cited by 125
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
Zuppinger, C., Timolati, F., & Suter, T. M. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0016-2 · Cited by 113
Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats
Matsui, H., Morishima, I., Numaguchi, Y., Toki, Y., Okumura, K., & Hayakawa, T. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00362-8 · Cited by 103
Cardiovascular Side-Effects of Modern Cancer Therapy
Minami, M., Matsumoto, S., & Horiuchi, H. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0632 · Cited by 80
Reversibility of Severe Left Ventricular Dysfunction Due to Doxorubicin Cardiotoxicity
Saini, J., RICH, M. W., & LYSS, A. P. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-6-814 · Cited by 79
de Nigris, F., Rienzo, M., Schiano, C., Fiorito, C., Casamassimi, A., & Claudio Napoli, A. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.12.010 · Cited by 62
Bosch, X., Sitges, M., Rovira, M., Ortiz-Pérez, J. T., & Esteve, J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.08.712 · Cited by 45
Wang, L.-X., Ideishi, M., Yahiro, E., Urata, H., Arakawa, K., & Saku, K. (2001) · Hypertension Research · doi:10.1291/hypres.24.179 · Cited by 34
Filho, F. V. G., Tan, D. M., Braga, J. C. F., Rodrigues, A., Waib, P. H., & Matsubara, B. B. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24000 · Cited by 9
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Self-citation
Metadata
- Authors
- Kalam, K., & Marwick, T. H.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 49
- Issue
- 13
- Pages
- 2900-2909
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2098886952
- Cited by
- 343
- References
- 56
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.